Vivos Inc. (RDGL)
OTCMKTS
· Delayed Price · Currency is USD
0.1255
+0.0066 (5.55%)
Apr 25, 2025, 4:00 PM EDT
Vivos Employees
Vivos had 1 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$27,995
Profits / Employee
-$2,910,448
Market Cap
56.90M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| Elite Pharmaceuticals | 64 |
| CytoDyn | 9 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Longduoduo Company | 49 |
Vivos News
- 4 days ago - Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025 - GlobeNewsWire
- 12 days ago - Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 4 months ago - Vivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide - GlobeNewsWire
- 4 months ago - Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial - GlobeNewsWire
- 6 months ago - Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM - GlobeNewsWire
- 9 months ago - Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA - GlobeNewsWire
- 10 months ago - Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials - GlobeNewsWire
- 1 year ago - Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation - GlobeNewsWire